业绩高速增长，创新管线持续兑现：—— 奥赛康三季报点评 2024-11-11 创新驱动转型，变革中等待突破：——奥 赛康首次覆盖报告 2024-03-11 | | 买入 （维持） | | --- | --- | | 股价（2025年05月06日） | 17.7 元 | | 目标价格 | 22.36 元 | | 52 周最高价/最低价 | 20.36/9.03 元 | | 总股本/流通 A 股（万股） | 92,816/92,815 | | A 股市值（百万元） | 16,428 | | 国家/地区 | 中国 | | 行业 | 医药生物 | | 报告发布日期 | 2025 年 05 月 07 日 | | | 1 周 | 1 月 | 3 月 | 12 月 | | --- | --- | --- | --- | --- | | 绝对表现% | -7.14 | -5.25 | 30.24 | 56.36 | | 相对表现% | -8.03 | -3.88 | 31.13 | 52.24 | | 沪深 300% | 0.89 | -1.37 | -0.89 | 4.12 | 奥赛康 002755.SZ 公司研究 | 年 ...

Core Viewpoint - Heng Rui Medicine has shown significant growth and innovation in 2024, achieving record-high revenues and profits, while also advancing its internationalization strategy through successful licensing agreements and a planned IPO in Hong Kong [1][5][14]. Financial Performance - In 2024, Heng Rui Medicine reported revenue of 27.985 billion yuan, a year-on-year increase of 22.63%, and a net profit of 6.337 billion yuan, up 47.28% [5]. - For Q1 2025, the company achieved revenue of 7.206 billion yuan, reflecting a 20.14% year-on-year growth, with a net profit of 1.874 billion yuan, increasing by 36.9% [5]. Innovation and R&D - Heng Rui Medicine has invested a total of 46 billion yuan in R&D as of Q1 2025, with innovative drug sales accounting for over 50% of total revenue [4][5]. - The company has 19 approved new molecular entity drugs and over 90 innovative products in clinical development, with 400 clinical trials ongoing [6]. Licensing and Partnerships - In 2024, Heng Rui Medicine secured two major licensing agreements totaling nearly $2 billion, marking a significant expansion in its business development (BD) strategy [8][9]. - The company has completed 14 licensing agreements, with potential total transaction amounts reaching approximately $14 billion in the last three years [10][11]. Internationalization Strategy - Heng Rui Medicine is pursuing a dual strategy of "innovation + internationalization," with plans to issue H-shares in Hong Kong to fund R&D and commercialization efforts [13][14]. - The company aims to optimize its international cooperation model and explore partnerships with multinational pharmaceutical companies and innovative startups [12][15]. Leadership Changes - The appointment of Feng Ji as the new president is seen as a move to accelerate Heng Rui Medicine's innovation and internationalization strategies [16]. Future Outlook - With a robust pipeline of innovative drugs and an expanding international presence, Heng Rui Medicine is positioned to play a more significant role in the global pharmaceutical market [17].

Core Viewpoint - BeiGene (06160) reported strong financial performance in Q1 2025, achieving revenue of 8.048 billion RMB, a year-on-year increase of 50.2%, driven by robust sales of its core products, Brukinsa® (Zebutinib) and Tislelizumab [1][2]. Financial Performance - The company transitioned from a loss to profit in both operating profit and total profit for Q1 2025, with significant improvement in operating cash flow [1]. - The full-year revenue guidance for 2025 remains unchanged, projected between 35.2 billion RMB and 38.1 billion RMB, supported by the anticipated strong growth of Brukinsa® in the U.S. and other key markets [1]. Product Performance - Brukinsa® achieved global sales of 5.692 billion RMB, a 63.7% increase year-on-year, with U.S. sales reaching 4.041 billion RMB, up 61.9% [2][3]. - In Europe, Brukinsa® sales were 836 million RMB, a 75.4% increase, while in China, sales reached 590 million RMB, a 43.1% increase [3]. Research and Development - The company is advancing its pipeline in hematologic malignancies, with the BCL2 inhibitor Sonrotoclax entering registration clinical trials and ongoing trials for various indications [3][4]. - BGB-16673, a BTK degrader, is in Phase 3 trials, expected to address BTK resistance issues [5]. PD-1 Product Development - Tislelizumab (替雷利珠单抗) generated sales of 1.245 billion RMB, a 19.3% increase, benefiting from new indications and increased hospital access [6]. - The product is approved in 46 markets globally, with over 1.5 million patients treated, and has recently gained reimbursement in 11 new markets [6]. Future Outlook - The company plans to host an investor R&D day on June 26, focusing on its breast cancer pipeline and broader oncology product portfolio [8]. - BeiGene will adopt a new English name, BeOne Medicines Ltd., and relocate its registration to Switzerland, expected to be completed later this year [8].

Core Viewpoint - Changshan Pharmaceutical is actively implementing a development strategy focused on expanding advantages, addressing shortcomings, developing new products, innovating drugs, and pursuing external growth in response to changes in the heparin industry [1][2]. Group 1: Business and Product Structure - Changshan Pharmaceutical is one of the few domestic companies with a complete heparin product industrial chain, engaging in the research, production, and sales of heparin crude products, active pharmaceutical ingredients, and formulations [1]. - The company’s main heparin products include heparin sodium crude, heparin sodium API, low molecular weight heparin calcium API, and various heparin injection solutions [1]. - The low molecular weight heparin calcium injection has maintained a leading market share for several years but has seen a decline in sales due to the impact of centralized procurement policies [1]. Group 2: Financial Performance - In the reporting period, Changshan Pharmaceutical achieved a revenue of 1.031 billion yuan, with low molecular weight heparin API contributing 145 million yuan, a year-on-year increase of 31.82% [2]. - Revenue contributions from ordinary heparin API and low molecular weight heparin formulations were 242 million yuan and 454 million yuan, respectively, while platform heparin formulations saw an 8.33% year-on-year growth to 54 million yuan [2]. Group 3: Innovation and R&D - The company views innovative drug research and development as key to overcoming current challenges, with a focus on the GLP-1 long-acting formulation, Aibennate injection, which has received acceptance for its marketing application from NMPA [2]. - If Aibennate is approved and launched, it is expected to reduce the company's reliance on heparin business for revenue and enhance profitability and risk resilience [2]. - Changshan Pharmaceutical is also advancing the development of two anti-tumor targeted original new drugs, CSCJC3456 and CSCJC4523, with CSCJC3456 having received NMPA approval for clinical trials in late-stage solid tumors [3]. Group 4: Future Strategy - For 2025, the company plans to maintain the sales of low molecular weight heparin formulations while focusing on increasing sales of heparin crude and API products [3]. - The company aims to actively promote the clinical progress and market launch of innovative drugs like Aibennate and CSCJC3456, with the goal of enhancing overall profitability [3].

证券代码： 300765 证券简称： 新诺威 编号：2025-03 | | □特定对象调研 □分析师会议 | | --- | --- | | 投 资 者 关 系 活 | □媒体采访 □业绩说明会 | | 动类别 | □新闻发布会 □路演活动 | | | □现场参观 √其他 关于终止资产重组事项的 | | | 投资者说明会 | | 参与单位名称 | 投资者网上提问 | | 时间 | 年 月 日（周二）下午 2025 5 6 15:30~16:30 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 | | | 用网络远程的方式召开投资者说明会 | | 上 市 公 司 接 待 | 1、董事长、总经理姚兵 | | | 2、董事、财务总监、董事会秘书戴龙 | | | 3、独立财务顾问代表栗灵芝 | | 人员姓名 | 4、独立财务顾问代表肖向南 | | | 5、交易对方代表 | | | 6、标的公司代表 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1.此事项的终止是否会对公司既定战略规划及未来业 | ...

Group 1 - The "Rice Blood" industrialization base project of He Yuan Bio has completed the main structure and is now entering the equipment installation and debugging phase, aiming for production by 2026, with an expected annual output of 12 million recombinant human serum albumin injection [1] - The completion of the project is strategically significant for meeting national health needs, reducing reliance on imports, and ensuring supply chain security [1] - The innovative drug sector is described as a challenging field, often referred to as "nine deaths and one life" due to the difficulties from research to market application [1] Group 2 - Several innovative drug companies are accelerating their presence in Optics Valley, with a reported signing amount of nearly 4.5 billion yuan for new projects in the first quarter of this year [1] - Shanghai Fukang Pharmaceutical plans to focus on commercializing innovative drugs and expanding overseas from Optics Valley, citing the area's vibrant and opportunity-rich environment [2] - The first eye gene therapy drug from Nufos Bio is currently in phase three clinical trials, with plans to strengthen its headquarters in Wuhan [2] Group 3 - The recombinant human serum albumin injection has completed phase three clinical trials, demonstrating efficacy comparable to human blood albumin, and is expected to be approved for market this year [3] - The process of innovation is described as a long-term effort, with recent breakthroughs attributed to years of persistence and support from the local ecosystem [3] Group 4 - The successful launch of new drugs is expected to generate revenue that can support the development of other local biopharmaceutical companies, creating a positive cycle within the industry [4] - Optics Valley has cultivated over 500 high-tech enterprises, 7 local listed companies, and 3 billion-level leading enterprises, maintaining a competitive edge in central China and nationally [4]

自A股上市以来累计现金分红约人民币80.29亿元。 本文为IPO早知道原创 作者｜ 罗宾 微信公众号｜ipozaozhidao 商业化层面， 截至 2024 年 12 月 31 日 ，公司已建立起约 9,000 人的自建销售和营销团队，在中 国制药企业中规模领先。销售网络覆盖中国 30 多个省级行政区的超过 22,000 家医院以及超过 200,000 家线下零售药店， 处于 行业领先 地位 。 近年来，恒瑞 加速全球化扩张步伐，充分释放产品矩阵和技术平台的潜力。 公司 已在包括美国、欧 洲、澳大利亚、日本及韩国等地区启动超过 20 项海外临床试验，产品在 40 多个国家实现商业化。 自 2018 年以来，公司与全球合作伙伴达成了 14 笔对外许可交易，涉及 17 个分子实体，总交易额 高达约 140 亿美元，首付款总额约为 6 亿 美元， 同时 还获 得 了若干合作伙伴的股权。 公司 于 2024 年 收入 录得 人民币 280 亿元，自 2014 年起的复合年增长率约为 14% ，远超同期 全球制药市场约 4% 的复合年增长率。创新药已成为公司收入的主要来源之一，其销售收入占总收 入的百分比从 2022 ...

公 华福证券 司 研 究 恩华药业（002262.SZ） 业绩符合预期，看好全年业绩稳健增长 投资要点： 事件：公司发布 2025 一季报，2025 一季报实现收入 15.1 亿元（同比 +11.3%），归母净利润 3.0 亿元（同比+13.4%），扣非净利润 3.0 亿元（同 比+12.2%）。 公 司 财 报 点 评 25Q1 各项费用率有所增加，股权激励费用影响公司利润：2025 年第 一季度公司销售毛利率和销售净利率分别为 74.7%和 19.9%。2025 年第一 季度，公司销售费用率、管理费用率、研发费用率和财务费用率分别为 33.6%（同比+1.5pct）、4.9%（同比+1.4pct）、12.7%（同比+2.2pct）、和-0.2% （同比+0.3pct）。公司管理费用同比增加主要系股权激励费用和特许权使用 费摊销增加所致，研发费用增加主要系研发投入增加和股权激励费用影响 所致。 | 日期 | 2025-04-30 | | --- | --- | | 收盘价： | 22.33 元 | | 总股本/流通股本(百万股) | 1,016.18/881.79 | | 流通 A 股市值(百万元) | 1 ...

证券研究报告 2025 年 5 月份股票组合 2025 年 5 月 6 日 重要提示： n 本文推荐理由和目标价仅供参考，并不构成买卖建议，股市有风险，投资需谨慎。 2025 年 5 月份股票组合 东莞证券 2025 年 4 月份股票组合表现 | 证券代码 | 证券名称 | 收盘价 | 收盘价 | 区间 | 区间最大 | 4 月份 | | --- | --- | --- | --- | --- | --- | --- | | | | （25/3/31） | （25/4/30） | 最高价 | 涨幅 | 涨幅 | | 601336 | 新华保险 | 51.50 | 48.11 | 52.96 | 2.83% | -6.58% | | 600036 | 招商银行 | 43.29 | 40.74 | 43.78 | 1.13% | -5.89% | | 000831 | 中国稀土 | 31.67 | 31.22 | 35.96 | 13.55% | -1.42% | | 601899 | 紫金矿业 | 18.12 | 17.46 | 18.76 | 3.53% | -3.64% | | 603288 | 海天味业 ...

Group 1 - The company reported Q1 2025 revenue of 1.51 billion yuan, a year-on-year increase of 11.3%, and a net profit attributable to shareholders of 300 million yuan, up 13.4% year-on-year [1] - In Q1 2025, the company's gross profit margin and net profit margin were 74.7% and 19.9%, respectively, with various expense ratios increasing, including sales expense ratio at 33.6% (up 1.5 percentage points year-on-year) [1] - The increase in management expenses was mainly due to higher stock incentive costs and amortization of franchise fees, while R&D expenses rose due to increased R&D investment and stock incentive costs [1] Group 2 - The company invested 721 million yuan in R&D in 2024, a year-on-year increase of 17.48%, with R&D personnel reaching 911, up 6.7% year-on-year [2] - The company has 14 innovative drug projects in development, with NH600001 completing Phase III clinical trials and expected to submit NDA within the year [2] - Other projects are at various clinical stages, including NHL35700 tablets and NH102 tablets in Phase II, and several others in Phase I or preclinical research [2] Group 3 - The company maintains revenue forecasts of 6.59 billion yuan, 7.69 billion yuan, and 8.93 billion yuan for 2025-2027, with growth rates of 16%, 17%, and 16% respectively [3] - Net profit attributable to shareholders is projected to be 1.31 billion yuan, 1.52 billion yuan, and 1.78 billion yuan for the same period, with growth rates of 15%, 16%, and 17% respectively [3] - The company is considered to be relatively undervalued, and given its growth potential and rich product pipeline, a "buy" rating is maintained [3]